Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25598759 | 0.98 | SIGMAR1 (0.39) | HTR6SIGMAR1MEN1KMT2ASLC18A3 | |
| SCHEMBL25596009 | 0.98 | SIGMAR1 (0.39) | HTR6SIGMAR1MEN1KMT2ASLC18A3 | |
| SCHEMBL13154267 | 0.94 | SIGMAR1 (0.40) | HTR6SIGMAR1MEN1KMT2ASLC18A3 | |
| SCHEMBL25672740 | 0.92 | MEN1 (0.36) | HTR6SIGMAR1MEN1KMT2AL3MBTL3 | |
| SCHEMBL24626947 | 0.91 | SIGMAR1 (0.42) | SIGMAR1MEN1KMT2ASLC18A3 | |
| SCHEMBL25595989 | 0.91 | SIGMAR1 (0.39) | HTR6SIGMAR1MEN1KMT2AL3MBTL3 | |
| SCHEMBL18133869 | 0.89 | MEN1 (0.39) | SIGMAR1MEN1KMT2ASLC18A3CYP2D6 | |
| SCHEMBL13069405 | 0.88 | MEN1 (0.43) | SIGMAR1MEN1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL2690030 | 0.86 | HTR6 (0.38) | HTR6SIGMAR1MEN1KMT2ASLC18A3 | |
| SCHEMBL10433619 | 0.85 | MEN1 (0.46) | MEN1KMT2AL3MBTL3L3MBTL1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | SCHRÖDINGER, INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | HTR6 915/4885SIGMAR1 3314/4885MEN1 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.